Galanthamine hydrobromide, Alkaloid acetylcholinesterase inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Acetylcholinesterase (AChE) also called acetylhydrolase is an enzyme with a molecular mass of about 67 kDa. It efficiently hydrolyzes the neurotransmitter acetylcholine into acetate and choline at synapses and neuromuscular junctions terminating neurotransmission. AChE is expressed in the brain muscles and other tissues with high concentration in cholinergic synapses. Its chemical structure includes an active site gorge critical for its function where the catalytic triad and peripheral anionic site reside. AChE inhibitors such as galantamine exploit this structure enhancing cholinergic function.

Biological function summary

Acetylcholinesterase plays an essential role in neural communication by regulating acetylcholine levels. It avoids overstimulation of cholinergic receptors maintaining balance in neurotransmission. Inhibition of this enzyme increases acetylcholine concentration which is beneficial in conditions like Alzheimer's disease. Galantamine an alkaloid functions as an acetylcholinesterase inhibitor and increases receptor activation. Although not part of a larger complex AChE closely interacts with other synaptic proteins for efficient neurotransmitter regulation.

Pathways

Acetylcholinesterase occupies a central position in the cholinergic pathway. This pathway is important for cognitive functions memory and muscle control. AChE interrelates with proteins such as butyrylcholinesterase which also hydrolyzes acetylcholine but with a different affinity and function. These enzymes through the cholinergic pathway influence both the central and peripheral nervous systems impacting cellular communication and synaptic plasticity.

Acetylcholinesterase has significant relevance to Alzheimer's disease and myasthenia gravis. Alzheimer's disease involves progressive cognitive decline where AChE inhibitors like galantamine hydrobromide provide symptomatic relief by enhancing cholinergic transmission. AChE also connects to neuropathologies due to its role in cholinergic deficits. In myasthenia gravis autoimmune attack against nicotinic receptors at the neuromuscular junction results in muscle weakness but boosting acetylcholine by inhibiting AChE can improve neuromuscular transmission.